Autopsy report · NCT03115801

A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

“Lack of accrual”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 11 months before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Weill Medical College of Cornell University

Sponsor type

University, hospital or other

Conditions

Metastatic Renal Cell Carcinoma; Metastatic Urothelial Carcinoma

Interventions

Nivolumab; Atezolizumab; Radiation & immunotherapy; Pembrolizumab

Participants

6

Sites

1

Countries

United States

Trials that died the same way

• Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma
  “Lack of adequate accrual.” (92% match in meaning)
• Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth
  “Inadequate accrual” (90% match in meaning)
• Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
  “Severe lack of accrual” (90% match in meaning)
• Metformin in Non Small Cell Lung Cancer (NSCLC)
  “Poor Accrual” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.